Europe's 2026 Heart Guideline Adds Two Kidney Tests: eGFR and uACR

Someone with a stent, or a heart failure diagnosis from the spring, is standing in a kitchen late in the evening reading a headline about heart disease harming the kidneys. The cardiology appointment covered a statin, a blood pressure target, an echo, a follow-up in six months. Kidneys did not come up. The headline suggests they should have.

The document behind that coverage is the European Society of Cardiology's first guideline on cardiovascular and kidney disease written jointly with the European Renal Association, published in the European Heart Journal on 28 August 2026. That the two organs are linked is not the news — clinicians have described the cardio-renal axis for decades. The lagging question, the one that survives the news cycle, is narrower and more useful: what does the guideline actually ask to happen inside an ordinary appointment.

This is not a trial, and reading it as one is the fastest way to misunderstand it. A guideline is a task force reading the accumulated evidence and issuing graded recommendations: a class for how strongly the panel backs the action, a level for the quality of evidence underneath it. Class I is the strongest class; Level A rests on multiple randomized trials or meta-analyses, Level C largely on expert consensus. The task force here was chaired by Kevin Damman in the Netherlands and William G. Herrington in the United Kingdom, with coordinators Jozine M. ter Maaten and Kaitlin J. Mayne, and it ran to more than a hundred contributors.

The guideline's framing number is an estimated 100 million people in Europe living with chronic kidney disease. Its organizing device is an acronym, STAMP on CKD — screening, triage and staging of CKD, addressing CKD risk, modifying approaches to cardiovascular management, and planning health services for the complexity that follows. Screening is deliberately the first letter.

One boundary matters before anything else: this is a European document. The ESC and ERA write for European practice, and nothing in it changes a US standard of care, which is set by other bodies working from their own reviews.

The screening recommendation reads: screening for CKD by testing for eGFR and albuminuria is recommended in all patients with CVD to identify those at risk of kidney failure and cardiovascular complications. It is graded Class I, Level A. The two components are graded the same way. A creatinine-based eGFR, calculated with a validated estimating equation, is recommended to assess kidney function and stage CKD — Class I, Level A. Measuring uACR in a spot morning urine sample is recommended to assess albuminuria and classify stage — also Class I, Level A.

The thresholds are the ones nephrology has used for years, and the guideline restates them: a GFR under 60 mL/min/1.73 m2, or a uACR at or above 3 mg/mmol (30 mg/g), are the definitions most commonly used. At the far end, category G5 — a persistently low GFR under 15 — represents kidney failure. The eGFR describes how much filtering capacity remains; the uACR describes whether the filter is leaking protein. They can disagree, which is the point of running both.

One number alone is not a diagnosis. The guideline asks for two measurements of eGFR and uACR over a period of at least three months to establish the chronicity that confirms CKD — and that recommendation is graded Class I, Level C, the consensus tier. The panel is confident about what to do; the evidence under the specific interval is expert judgment rather than trial data.

Screening earns its place only if finding something changes the response, and this is where the guideline spends its evidence. Many patients found to have CKD should then have their risk of kidney failure managed with an ACE inhibitor or an angiotensin-II receptor blocker plus a sodium-glucose cotransporter-2 inhibitor. For chronic heart failure with CKD, an SGLT2 inhibitor is recommended independent of left ventricular ejection fraction — the same drug class, regardless of which kind of heart failure. In heart failure with preserved ejection fraction, a non-steroidal mineralocorticoid receptor antagonist is added. For patients with both diabetes and CKD, the document reaches further, to a non-steroidal MRA and a GLP-1 receptor agonist.

The results also feed prediction rather than sitting in a chart. The guideline names the Kidney Failure Risk Equation for kidney outcomes and the SCORE2 family, including SCORE2-OP and SCORE2-HF, for cardiovascular risk. Both take kidney measurements as inputs, which is the mechanical reason a missing uACR degrades a cardiovascular risk estimate and not only a kidney one.

The recommendation is graded on the tests as identifiers of risk. The guideline does not report a randomized trial of screening itself — of taking two populations of cardiovascular patients, screening one, and comparing what happened to them. That is a real distinction, and it is the sort of gap that a Class I, Level A rating can obscure for a reader who takes the letters to mean the whole strategy was trialled end to end.

It is also silent on cadence and on cost. No interval appears for repeating the pair when the first results are normal, and the document does not address what the tests cost or how reliably they are available across European health systems. The task force is explicit about one further limit of the evidence base: more randomized trials are needed in patients on kidney replacement therapy, and particularly in dialysis populations.

The substance of the guideline is administrative more than scientific, and that is not a criticism. Both tests already exist in every hospital laboratory in Europe. The eGFR arrives more or less automatically with routine blood work; the uACR is the one that gets skipped, because it requires a urine sample in a clinic organized around blood draws and imaging. Putting it in a cardiology recommendation table at the strongest available grade is an attempt to close a gap of habit rather than of knowledge.

For a patient reading the coverage, the durable content is the vocabulary. Two named tests, two thresholds, a three-month confirmation rule, and a set of drug classes that a result can unlock. Those are the terms in which the question is actually settled in a consulting room, and they do not expire when the news cycle does.

The interesting thing about this guideline is how little of it is new science and how much of it is plumbing. Cardiologists have known for years that kidney function predicts cardiovascular outcomes; what changes here is that a urine test now sits in a cardiology recommendation table at Class I, Level A, in the first document the ESC has written jointly with European nephrology. That is worth something, because the uACR is precisely the test that falls through the cracks of a clinic built around blood draws and imaging, and because both the Kidney Failure Risk Equation and the SCORE2 tools degrade quietly without it. The honest soft spot is the three-month confirmation rule, graded Level C: the panel is sure enough of the principle and candid that the specific interval is consensus rather than evidence, and the absent guidance on when to re-test a normal result leaves the same judgment to whoever runs the appointment. The recommendation is graded on the tests, not on a trial of screening, and readers deserve to see that distinction rather than infer a settled strategy from two strong letters. Whether US bodies follow is a separate question with a separate evidence review, and this document does not answer it.